MANKIND vs SAILIFE: Stock Comparison
MANKIND PHARMA is the larger company by market capitalisation. MANKIND PHARMA shows a lower P/E and faster revenue growth, while SAI LIFE SCIENCES shows a higher ROE, lower leverage and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
MANKIND leads 5; SAILIFE leads 5 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | MANKIND | SAILIFE |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | MANKIND | SAILIFE |
|---|---|---|
| Live Price | ₹2,469.3 | ₹1,495.7 |
| Day Change | -0.83% | 0.57% |
| Volume | 7.29 L | 2.83 L |
| 52-Week High | ₹2,642 | ₹1,697 |
| 52-Week Low | ₹1,909.7 | ₹783.85 |
| Distance from 52W High | -6.54% | -11.86% |
Valuation
| Metric | MANKIND | SAILIFE |
|---|---|---|
| Market Cap | ₹1.02 L Cr | ₹31,757 Cr |
| P/E Ratio | 45.19x | 87.32x |
| P/B Ratio | 5.78x | 12.75x |
| EPS | ₹13.9 | ₹3.45 |
| Book Value | ₹401 | ₹117 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | MANKIND | SAILIFE |
|---|---|---|
| Revenue Growth (TTM YoY) | 11.8% | 3.9% |
| EPS Growth (TTM YoY) | 31.7% | 17.6% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | MANKIND | SAILIFE |
|---|---|---|
| ROE | 11.7% | 13.62% |
| ROCE | 10.93% | 14.49% |
| Net Margin | 13.34% | 15.81% |
| Operating Margin | 20.73% | 22.7% |
| Debt to Equity | 0.38x | 0.04x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | MANKIND | SAILIFE |
|---|---|---|
| Promoter Holding | 72.62%▼ 0.01 pp | 32.85%▼ 0.02 pp |
| FII Holding | 9.37%▼ 0.08 pp | 19.91%▲ 0.26 pp |
| DII Holding | 15.56%▲ 0.17 pp | 32.32%▼ 0.39 pp |
| Public Holding | 2.45%▼ 0.08 pp | 13.26%▲ 0.15 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: MANKIND PHARMA and SAI LIFE SCIENCES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.